Spatial and temporal cancer evolution: causes and consequences of tumour diversity

Clinical Medicine, Journal of the Royal College of Physicians of London

Volumn 14, Issue 6, 2014, Pages s33-s37

  Hiley, Crispin T ^a   Swanton, Charles ^b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Cancer; evolution; heterogeneity; resistance

Indexed keywords

CHEMISTRY; DISEASE COURSE; DNA SEQUENCE; DRUG RESISTANCE; GENETICS; HUMAN; MOLECULAR EVOLUTION; NEOPLASM; ONCOGENESIS AND MALIGNANT TRANSFORMATION; PATHOLOGY; PHYLOGENY; SPATIOTEMPORAL ANALYSIS;

DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; EVOLUTION, MOLECULAR; HUMANS; NEOPLASMS; NEOPLASTIC PROCESSES; PHYLOGENY; SEQUENCE ANALYSIS, DNA; SPATIO-TEMPORAL ANALYSIS;

EID: 84938366051     PISSN: 14702118     EISSN: 14734893     Source Type: Journal    
DOI: 10.7861/clinmedicine.14-6-s33     Document Type: Article

References (30)

1. Stehelin, D, Varmus, HE, Bishop, JM, et al. DNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA. Nature 260 (1976), 170–173 10.1038/260170a0.
2. Nowell, PC, The clonal evolution of tumor cell populations. Science 194 (1976), 23–28 10.1126/science.959840.
3. Lawrence, MS, Stojanov, P, Polak, P, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499 (2013), 214–218 10.1038/nature12213.
4. Cahill, DP, Kinzler, KW, Vogelstein, B, et al. Genetic instability and darwinian selection in tumours. Trends Cell Biol 9 (1999), 57–60 10.1016/S0962-8924(99)01661-X.
5. Campbell, PJ, Yachida, S, Mudie, LJ, et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 467 (2010), 1109–1113 10.1038/nature09460.
6. Anderson, K, Lutz, C, van Delft, FW, et al. Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature 469 (2011), 356–361 10.1038/nature09650.
7. Navin, N, Kendall, J, Troge, J, et al. Tumour evolution inferred by single-cell sequencing. Nature 472 (2011), 90–94 10.1038/nature09807.
8. Alexandrov, LB, Stratton, MR, Mutational signatures: the patterns of somatic mutations hidden in cancer genomes. Curr Opin Genet Dev 24C (2014), 52–60 10.1016/j.gde.2013.11.014.
9. Hanahan, D, Weinberg, RA, Hallmarks of cancer: the next generation. Cell 144 (2011), 646–674 10.1016/j.cell.2011.02.013.
10. Burrell, RA, McGranahan, N, Bartek, J, et al. The causes and consequences of genetic heterogeneity in cancer evolution. Nature 501 (2013), 338–345 10.1038/nature12625.
11. The Cancer Genome Atlas. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487 (2012), 330–337 10.1038/nature11252.
12. Dalgliesh, GL, Furge, K, Greenman, C, et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 463 (2010), 360–363 10.1038/nature08672.
13. Varela, I, Tarpey, P, Raine, K, et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 469 (2011), 539–542 10.1038/nature09639.
14. Dewhurst, SM, McGranahan, N, Burrell, RA, et al. Tolerance of whole-genome doubling propagates chromosomal instability and accelerates cancer genome evolution. Cancer Discov 4 (2014), 175–185 10.1158/2159-8290.CD-13-0285.
15. Carter, SL, Eklund, AC, Kohane, IS, et al. A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat Genet 38 (2006), 1043–1048 10.1038/ng1861.
16. McGranahan, N, Burrell, RA, Endesfelder, D, et al. Cancer chromosomal instability: therapeutic and diagnostic challenges. EMBO Rep 13 (2012), 528–538 10.1038/embor.2012.61.
17. Baca, SC, Prandi, D, Lawrence, MS, et al. Punctuated evolution of prostate cancer genomes. Cell 153 (2013), 666–677 10.1016/j.cell.2013.03.021.
18. Stephens, PJ, Greenman, CD, Fu, B, et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 144 (2011), 27–40 10.1016/j.cell.2010.11.055.
19. Ding, L, Ley, TJ, Larson, DE, et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 481 (2012), 506–510 10.1038/nature10738.
20. Hunter, C, Smith, R, Cahill, DP, et al. A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. Cancer Res 66 (2006), 3987–3991 10.1158/0008-5472.CAN-06-0127.
21. Gerlinger, M, Rowan, AJ, Horswell, S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366 (2012), 883–892 10.1056/NEJMoa1113205.
22. Gerlinger, M, Horswell, S, Larkin, J, et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat Genet 46 (2014), 225–233 10.1038/ng.2891.
23. Yachida, S, Jones, S, Bozic, I, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467 (2010), 1114–1117 10.1038/nature09515.
24. Niikura, N, Liu, J, Hayashi, N, et al. Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. J Clin Oncol 30 (2012), 593–599 10.1200/JCO.2010.33.8889.
25. Su, KY, Chen, HY, Li, KC, et al. Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. J Clin Oncol 30 (2012), 433–440 10.1200/JCO.2011.38.3224.
26. Landau, DA, Carter, SL, Stojanov, P, et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 152 (2013), 714–726 10.1016/j.cell.2013.01.019.
27. Verhaak, RG, Hoadley, KA, Purdom, E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma -characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17 (2010), 98–110 10.1016/j.ccr.2009.12.020.
28. Sottoriva, A, Spiteri, I, Piccirillo, SG, et al. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci USA 110 (2013), 4009–4014 10.1073/pnas.1219747110.
29. Ng, CK, Weigelt, B, A'Hern, R, et al. Predictive performance of microarray gene signatures: impact of tumor heterogeneity and multiple mechanisms of drug resistance. Cancer Res, 2014 in press.
30. Greaves, M, Maley, CC, Clonal evolution in cancer. Nature 481 (2012), 306–313 10.1038/nature10762.